key: cord-0789366-46ofgovg
authors: Wang, Yeming; Gu, Xiaoying; Xu, Jiuyang; Cao, Bin; Wang, Chen
title: Remdesivir and COVID-19 – Authors' reply
date: 2020-10-01
journal: Lancet
DOI: 10.1016/s0140-6736(20)32015-8
sha: 388462f3dc0cfbd2d6a1cc38472aba1ef658bebf
doc_id: 789366
cord_uid: 46ofgovg

nan

only a limited number of new-onset severe patients. A detailed recruitment process has been reported elsewhere. 5 The suggestion made by Jessie K Edwards and colleagues to report the effect of remdesivir stratified by lopinavir-ritonavir is important, although the potential effect of lopinavir-ritonavir was not confirmed in COVID-19 patients. Evaluating whether an interaction exists between lopinavir-ritonavir and remdesivir is still important and can also provide evidence for the feasibility of factorial trial of these two drugs. The result from our trial showed that there was no statis tically significant interaction between lopinavir-ritonavir and remdesivir on time to clinical improvement (p=0·35).

We appreciate the possible explanation raised by Lei-Yun Wang and colleagues that the genetic backgrounds of patients might be one of the reasons for discrepant results between the Chinese and American remdesivir clinical trials. 1,6, . The relationship between seven pharmacogenes and the plasma concentration of remdesvir in two populations should be confirmed. Whether the different strains of severe acute respiratory syndrome coronavirus 2 between China and the USA contribute to the discrepant effect of remdesivir also needs to be confirmed. McCreary and Angus 7 speculate that differences in study design could be the reason to explain the variation in results from the trials of remdesivir. They also provide several valuable questions about the variable effects of remdesivir in different trials. Although the conclusions between the three trials have discrepancies, 1,6,8 we still want to emphasise that the main findings from remdesivir trials showed similar but limited beneficial effect of remdesivir in patients with COVID-19.

We declare no competing interests.

Yeming Wang, Xiaoying Gu, Jiuyang Xu, *Bin Cao, Chen Wang caobin_ben@163.com

The mutational constraint spectrum quantified from variation in 141 456 humans

DrugBank 5.0: a major update to the DrugBank database for 2018

The 2019 novel coronavirus resource

We thank the clinicians and researchers around the world for their comprehensive interpretation of the results of our randomised controlled trial of remdesivir for COVID-19. 1 They shared valuable thoughts from different perspectives according to related evidence from in vitro and animal models, and pharmacogenomic studies. A suggestion was made for subgroup analyses by concomitant lopinavirritonavir use. Concerns for not reaching the predetermined sample size in our study were also expressed. These comments are appreciated and helpful for future conduct and interpretation of COVID-19 therapy studies.Matthew Glaus and Serena Von Ruden point out that the therapeutic effect of remdesivir might be lost when treat ment initiation was delayed, based on results from animal studies. 2,3 We certainly agree that initiating remdesivir at an earlier stage might contribute to better clinical benefits. However, it is challenging to initiate early antiviral therapy due to possible delays in screening and diagnosis of COVID-19. In our trial, we set 12 days from symptom onset as one of the inclusion criteria. 4 Alicia Dennis questioned the fact that our trial was terminated by March 12, 2020, due to reasons we have stated and further commented that ongoing study recruitment would probably have been possible. Although the number of confirmed COVID-19 patients at the time was still large in Wuhan, China, there were

Samira Asma and colleagues 1 show the complexity of the global monitoring of health-related Sustainable Develop ment Goals (SDGs) and argue for convergence, harmonisation, and strong data science. However, many offspring of SDG monitoring systems have emerged beyond the monitoring of UN SDG indicators, either at supra-national level